In addition, although treatment with a VCit-based anti-HER2 ADC showed poor therapeutic effect, treatment with the stable EVCit ADC led to complete remission in two xenograft mouse models of HER2-positive breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.